Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces phase II denosumab results

Amgen announces phase II denosumab results

17th December 2007

Amgen has announced the results of a phase III clinical study in its denosumab oncology development programme, with the compound found to increase bone density (BMD) throughout the skeleton in non-metastatic breast cancer patients receiving adjuvant aromatase inhibitor therapy.

Speaking at the late-breaking session of the annual San Antonio Breast Cancer Symposium, the firm reported that the drug increased the BMD of the cortical bone – the dense outer skeleton shell – as well as the trabecular bone – the spongy bone matrix.

Densoumab is a fully human monoclonal antibody that targets the Rank Ligand mediator of osteoclasts. It uses a targeted mechanism that does not incorporate into bone matrix and affects all stages of osteoclast activity.

Roger M Perlmutter, executive vice-president of research and development at Amgen, said: “This data on denosumab evaluating its effect on BMD throughout the skeleton, including cortical sites, should be encouraging to clinicians who witness the devastating effects of cancer and cancer treatment on their patients’ bones.”

He added that the results of this study provide a indication of the potential of the compound to manage bone disease in a number of types and stages of cancer.

In July 2007, Amgen signed an agreement with Daiichi Sankyo for the development and marketing of denosumab.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.